Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kewaunee Scientific Corporation files regulatory reports that document operating results, governance actions and material corporate disclosures for its laboratory furniture and biosafety products business. Recent Form 8-K reports cover earnings releases, fiscal-quarter financial condition disclosures, non-GAAP reconciliations, earnings announcement notices, and Regulation FD investor presentation materials.
The company's filings also disclose shareholder voting results, director appointments, auditor ratification, advisory compensation votes, and the registered common stock traded under KEQU on The Nasdaq Global Market. Business descriptions in the filings identify Kewaunee's laboratory casework, fume hoods, modular systems, workstations, benches, biological safety cabinets, epoxy resin surfaces and sinks, and Nu Aire laboratory products.
Thomas David Hull III, President, CEO and director of Kewaunee Scientific Corp (KEQU), reported two open-market sales of common stock on September 23-24, 2025. He sold 721 shares on 09/23/2025 at a weighted-average price shown as $44 and an additional 1,000 shares on 09/24/2025 at a weighted-average price shown as $43.62. After the September 23 trade his beneficial ownership was 42,573 shares and after the September 24 trade it was 41,573 shares. The form was signed by an attorney-in-fact on 09/24/2025. The filing includes a note that reported prices are weighted averages and that the filer will provide breakdowns on request.
Thomas David Hull III, who serves as President, CEO and a director of Kewaunee Scientific Corp (KEQU), reported two insider sales of common stock on September 18 and 19, 2025. On 09/18/2025 he sold 652 shares at a weighted average price of $46 (price range $46.00–$46.03), leaving him with 44,067 shares beneficially owned after that transaction. On 09/19/2025 he sold 773 shares at a weighted average price of $45.34 (price range $45.21–$45.71), with 43,294 shares reported beneficially owned following that sale. The Form 4 was executed by an attorney-in-fact and includes standard explanatory remarks about weighted average pricing.
Thomas David Hull III, who serves as President, CEO and a director of Kewaunee Scientific Corp (KEQU), reported two insider sales of common stock on September 18 and 19, 2025. On 09/18/2025 he sold 652 shares at a weighted average price of $46 (price range $46.00–$46.03), leaving him with 44,067 shares beneficially owned after that transaction. On 09/19/2025 he sold 773 shares at a weighted average price of $45.34 (price range $45.21–$45.71), with 43,294 shares reported beneficially owned following that sale. The Form 4 was executed by an attorney-in-fact and includes standard explanatory remarks about weighted average pricing.
Campbell John Jette, identified as a director of Kewaunee Scientific Corp (KEQU), filed an initial Section 16 Form 3 reporting the transaction date 09/10/2025. The filing states no securities are beneficially owned by the reporting person and includes a power of attorney (Exhibit 24) with the form signed by an attorney-in-fact on 09/11/2025. This is an initial ownership disclosure showing the director currently holds no reportable equity.
Kewaunee Scientific announced the appointment of Mr. Campbell to its Board and approved amended bylaws. Mr. Campbell brings extensive finance and restructuring experience from roles at Carl Marks Advisors and prior executive positions at Griffin LLC, PepsiCo and Frito-Lay, and is a certified public accountant with decades in public accounting and corporate finance. The Board determined he meets Nasdaq and SEC independence and financial literacy requirements and has named him to the Audit Committee.
The company said Mr. Campbell will be paid under the standard non-employee director program and will receive a pro-rated equity grant for fiscal 2026. The Board also amended Section 5.02 of the Bylaws to set the Board size at a minimum of five and maximum of nine directors, with the exact number fixed by Board resolution.
Kewaunee Scientific Corporation filed a current report to let investors know it has released financial results for the first quarter of its fiscal year 2026. The company states that these results were announced in a press release dated September 10, 2025, which is provided as Exhibit 99.1.
The report explains that this press release is being furnished, rather than filed, which limits how it is treated under securities laws. Kewaunee’s common stock continues to trade on the Nasdaq Global Market under the symbol KEQU.
Kewaunee Scientific Corporation reported the results of its Annual Meeting of Shareholders held on August 27, 2025. Shareholders re-elected Class III directors Margaret B. Pyle and Donald F. Shaw, with Pyle receiving 1,633,067 votes for and 189,229 withheld, and Shaw receiving 1,730,171 votes for and 92,125 withheld, along with 537,449 broker non-votes for each nominee.
Shareholders ratified the appointment of Forvis Mazars, LLP as independent auditors for fiscal 2026, with 2,356,636 votes for, 2,119 against, and 990 abstentions. On an advisory basis, shareholders approved the compensation of the named executive officers with 1,448,991 votes for, 103,177 against, 270,128 abstentions, and 537,449 non-votes.
In an advisory vote on the frequency of future say-on-pay votes, shareholders favored holding the vote every one year, with 1,512,884 votes for one year, 1,194 for two years, 306,985 for three years, 1,233 abstentions, and 537,449 non-votes. The company will include an annual non-binding advisory vote on executive compensation in its proxy materials consistent with this outcome and the Board’s recommendation.
Kewaunee Scientific Corporation filed a current report to let investors know when it will share its next results. The company announced that it plans to release its first quarter fiscal 2026 earnings on September 10, 2025. This update is provided through a press release that is attached to the report as an exhibit and incorporated by reference.
Kewaunee Scientific Corporation furnished an investor presentation and related script in connection with its virtual Annual Meeting of Shareholders held at 11:00 a.m. Eastern time on August 27, 2025. These materials, attached as Exhibits 99.1 and 99.2, are also available in the Investor Information section of the company’s website and a replay of the audio webcast of the meeting will remain accessible for about one year. The company uses non-GAAP financial measures in the presentation and provides reconciliations to comparable GAAP measures in the same location. The materials also include forward-looking statements, and the company points investors to its Form 10-K for the year ended April 30, 2025 and other SEC filings for a discussion of risk factors that could cause actual results to differ.
Kewaunee Scientific Corp. (KEQU) – Form 4 filed 07/28/2025 reports two open-market sales by CFO Donald T. Gardner III on 07/24/2025.
- Sold 2,096 common shares at a weighted avg. $58.34 (range $58.00-$58.97).
- Sold 904 common shares at a weighted avg. $59.18 (range $59.00-$59.45).
- Total shares sold: 3,000; estimated proceeds ≈ $175k.
- Direct ownership dropped from 17,564 to 14,564 shares, a reduction of roughly 17%.
No derivative transactions were reported and the filing offers no commentary on the purpose of the sales.